Jason Xiao

Jason Xiao

Auto-generated profile, based on publicly available information

Jason Xiao

Pritzker School of Medicine, University of Chicago, Chicago, IL, United States

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2025 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
RKRobert C. Keskey
Robert C. Keskey
JXJason Xiao
Jason Xiao
SHSanjiv Hyoju
Sanjiv Hyoju
ALAdam Lam
Adam Lam
DKDaniel Kim
Daniel Kim
JAJohn C. Alverdy
John C. Alverdy

6 May 2023 in The American Journal of Pathology
Verified
Journal Article
Closed access
JXJason Xiao
Jason Xiao
JZJason Y. Zhang
Jason Y. Zhang
WLWendy Luo
Wendy Luo
PHP. Cody He
P. Cody He
Dimitra SkondraDimitra Skondra
Dimitra Skondra

6 October 2023 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
RTRebecca E. Tanenbaum
Rebecca E. Tanenbaum
JXJason Xiao
Jason Xiao
MQMary Qiu
Mary Qiu
To report on delayed-onset hyphema following intravitreal injection of dexamethasone implant Ozurdex® in eyes with a history of gonioscopy-assisted transluminal trabeculotomy (GATT). We describe two cases of hyphema occurring within one day following Ozurdex® implantation in eyes that had undergone GATT at least one year prior. One case responded well to medical management, while the other required anterior chamber paracentesis for intraocular pressure (IOP) control. Both patients achieved normalization of IOP following resolution of the hyphema, and have not had recurrence. We propose that transient hypotony immediately after Ozurdex® injection may lead to a reflux of blood from the episcleral venous network into the anterior chamber in eyes with prior ab interno trabeculotomy. Glaucoma and retina specialists should be aware of this potential complication to guide follow up and management in the post-injection period for these patients.

7 February 2025 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
JXJason Xiao
Jason Xiao
MQMary Qiu
Mary Qiu
To evaluate the impact of intravitreal dexamethasone implantation (Ozurdex) on ocular hypertension (OHT) development and characterize its management with non-invasive or minimally-invasive modalities. Chart review was performed for patients who received Ozurdex implantation between September 2016 to September 2023. Patients were excluded if they had ever been diagnosed with neovascular glaucoma or received a different intravitreal corticosteroid prior to Ozurdex injection or 6 months afterwards. The analysis included 171 Ozurdex implants (n = 61 patients, n = 74 eyes) for analysis. Patients were followed for an average of 326 ± 45 days. The rise in IOP was greatest 2- and 3-months post-injection. OHT occurred following 40 (23.3 %) Ozurdex implants. To lower IOP, medical drops were initiated after 17 (10.0 %) implants. Selective laser trabeculoplasty was performed in 2 (1.2 %) cases. Minimally-invasive glaucoma surgeries (MIGS) were utilized in 7 (4.1 %) cases. Patients >60 years old were at increased odds of developing OHT, whereas patients treated for retinal vein occlusion were less likely to develop OHT compared to patients treated for diabetic macular edema. Patient-specific characteristics, including age and treatment indication, may confer different risk for developing OHT following Ozurdex implantation. Ozurdex-induced OHT can be safely and effectively managed using a combination of medical therapy, laser trabeculoplasty, and angle-based MIGS. This study supports an increasing range of alternative approaches for addressing elevated IOP or postponing surgeries linked with higher risks.

16 December 2024 in Journal of Glaucoma
Verified
Journal Article
Closed access
JXJason Xiao
Jason Xiao
ZSZhuangjun Si
Zhuangjun Si
MQMary Qiu
Mary Qiu
Précis: Resident-performed same-day bilateral selective laser trabeculoplasty are safe and effective for patients with primary open angle glaucoma or ocular hypertension. Purpose: To assess the efficacy and safety of resident-performed same-day bilateral 360-degree selective laser trabeculoplasty (SLT). Patients and Methods: A retrospective chart review was performed for patients who received bilateral, resident-performed SLT at the University of Chicago from January 1, 2020 to December 31, 2022 under the supervision of 1 glaucoma surgeon (M.Q.). Patients were included in this analysis if they underwent same-day bilateral 360-degree SLT and had at least 6 months of follow-up available. Data were collected on visual acuity, intraocular pressure (IOP), number of IOP-lowering medications, and complications for up to 2 years after the procedure. Results: There were 48 patients included in this analysis, and the diagnosis was either primary open angle glaucoma (85.4%) or ocular hypertension (14.6%). For patients whose SLT goal was to lower IOP (n=38), the mean baseline IOP in right eyes (OD) was 19.2 mm Hg on 2.1 medications, and in left eyes (OS) was 19.5 mm Hg on 2.1 medications. At the final follow-up (mean 519 d), the mean IOP in the right eyes was 15.8 mm Hg on 2.0 medications, and in the left eyes was 15.8 mm Hg OS on 2.2 medications, resulting in an IOP reduction of 17.6% OD and of 18.8% OS. For patients whose SLT goal was to lower medication number (n=10), the mean baseline IOP in right eyes was 16.7 mm Hg on 2.3 medications, and in left eyes was 16.4 mm Hg OS on 2.3 medications. At the final follow-up (mean 528 d), the mean IOP in the right eye was 17.6 mm Hg on 1.1 medications, and in the left eye was 16.3 mm Hg OS on 1.1 medications, resulting in a medication reduction of 1.1 fewer medications OD and 1.1 fewer medications OS. One patient experienced a 6 mm Hg IOP rise above baseline 4 weeks after SLT, and another developed 2 small, focal areas of peripheral anterior synechiae. Six (12.5%) patients underwent additional IOP-lowering surgery during the chart review period. Conclusions: Resident-performed same-day bilateral 360-degree SLT was effective and associated with minimal complications, with rates comparable to those of attending-performed SLT in the literature. SLT can be individualized to patients’ goals of IOP-lowering or medication reduction. Teaching institutions can consider incorporating this method of education for appropriate patients with primary open angle glaucoma or ocular hypertension.

30 April 2026 in Asian/Pacific Island Nursing Journal
Verified
Journal Article
Open access
JXJason Xiao
Jason Xiao
JYJielu Yu
Jielu Yu
ESErin Staab
Erin Staab
NTNikita C Thomas
Nikita C Thomas
WWWen Wan
Wen Wan
NLNeda Laiteerapong
Neda Laiteerapong
Background: Asian American and Pacific Islander populations are disproportionately affected by diabetes. Objective: The purpose of this study was to assess the efficacy of nonpharmacologic interventions in reducing hemoglobin A 1c (HbA 1c ) levels among Asian American or Pacific Islander individuals with type 2 diabetes. Methods: A systematic review was conducted using the PubMed, Scopus, PsycInfo, and CINAHL databases, covering studies published from 1985 to 2019. Eligible studies were randomized controlled trials that evaluated nonpharmacologic interventions in outpatient settings for adults with type 2 diabetes in the United States, with at least 50% Asian American or Pacific Islander participants. Data extraction and risk of bias assessment were independently performed by 2 reviewers for each trial. The Cochrane Collaboration risk of bias tool and the Grading of Recommendations, Assessment, Development, and Evaluation approach were used to evaluate quality. Random-effects meta-analyses were conducted to estimate pooled effect sizes. Results: A total of 1835 articles were screened, with 9 randomized controlled trials meeting the inclusion criteria, comprising 1492 participants, with a median follow-up duration of 6 (IQR 3-12) months. Interventions included diabetes self-management education, bilingual counseling, glucose or weight monitoring, motivational interviewing, and financial support, often tailored to the cultural context of the participants. Pooled analysis of the 9 trials demonstrated a significant average HbA 1c reduction of −0.39% (95% CI −0.64% to −0.14%; I ²=65%). Seven studies were judged to have a low risk of bias, 1 study had some concerns, and 1 study was assessed as high risk. The overall strength of evidence was high. Conclusions: Nonpharmacologic interventions substantively reduced HbA 1c levels in Asian American or Pacific Islander individuals with type 2 diabetes, particularly when culturally and linguistically tailored.